GeoVax Labs Inc. (NASDAQ:GOVX) Sees Large Decrease in Short Interest

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 210,698 shares, a decline of 22.7% from the February 12th total of 272,648 shares. Based on an average trading volume of 160,711 shares, the short-interest ratio is presently 1.3 days. Currently, 11.6% of the shares of the company are sold short. Currently, 11.6% of the shares of the company are sold short. Based on an average trading volume of 160,711 shares, the short-interest ratio is presently 1.3 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of GeoVax Labs in the 1st quarter valued at approximately $27,000. Sabby Management LLC bought a new stake in GeoVax Labs in the third quarter valued at approximately $313,000. Armistice Capital LLC bought a new position in GeoVax Labs during the third quarter worth about $253,000. Hudson Bay Capital Management LP bought a new position in shares of GeoVax Labs during the 3rd quarter valued at about $47,000. Finally, Renaissance Technologies LLC acquired a new position in shares of GeoVax Labs in the fourth quarter valued at approximately $104,000. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Stock Performance

NASDAQ GOVX traded down $0.04 during trading on Tuesday, reaching $1.67. 25,103 shares of the company traded hands, compared to its average volume of 151,284. GeoVax Labs has a 1-year low of $1.26 and a 1-year high of $37.75. The stock’s 50 day moving average price is $2.49 and its two-hundred day moving average price is $8.93. The company has a market cap of $3.03 million, a price-to-earnings ratio of -0.05 and a beta of 3.82.

Wall Street Analyst Weigh In

GOVX has been the topic of several recent research reports. D. Boral Capital reissued a “hold” rating on shares of GeoVax Labs in a report on Thursday, February 19th. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $187.50.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.